APO Research
Talk to an analyst

APO RESEARCH · REPORT

Type I Hyperlipoproteinemia Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Type I Hyperlipoproteinemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025186 pages

Choose your research edition.

Industry ResearchType I Hyperlipoproteinemia Drug Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Type I Hyperlipoproteinemia Drug Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Type I Hyperlipoproteinemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Type I Hyperlipoproteinemia Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Type I Hyperlipoproteinemia Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Type I Hyperlipoproteinemia Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Type I Hyperlipoproteinemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Type I Hyperlipoproteinemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Type I Hyperlipoproteinemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Type I Hyperlipoproteinemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Type I Hyperlipoproteinemia Drug include Aegerion Pharmaceuticals, Inc., Catabasis Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., uniQure N.V. and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Type I Hyperlipoproteinemia Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Type I Hyperlipoproteinemia Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Type I Hyperlipoproteinemia Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Type I Hyperlipoproteinemia Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Type I Hyperlipoproteinemia Drug Segment by Company

Aegerion Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

uniQure N.V.

Novartis AG

Type I Hyperlipoproteinemia Drug Segment by Type

Pradigastat Sodium

Lomitapide Mesylate

Alipogene Tiparvovec

ISIS-APOCIIIRx

CAT-2003

Others

Type I Hyperlipoproteinemia Drug Segment by Application

Hospital

Clinic

Others

Type I Hyperlipoproteinemia Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Type I Hyperlipoproteinemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Type I Hyperlipoproteinemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Type I Hyperlipoproteinemia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Type I Hyperlipoproteinemia Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Type I Hyperlipoproteinemia Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Type I Hyperlipoproteinemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Type I Hyperlipoproteinemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Type I Hyperlipoproteinemia Drug Industry Trends Table 2. Type I Hyperlipoproteinemia Drug Industry Drivers Table 3. Type I Hyperlipoproteinemia Drug Industry Opportunities and Challenges Table 4. Type I Hyperlipoproteinemia Drug Industry Restraints Table 5. Global Type I Hyperlipoproteinemia Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Type I Hyperlipoproteinemia Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Type I Hyperlipoproteinemia Drug Sales Market Share by Manufacturers Table 9. Global Type I Hyperlipoproteinemia Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Type I Hyperlipoproteinemia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Type I Hyperlipoproteinemia Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Type I Hyperlipoproteinemia Drug Manufacturers, Product Type & Application Table 13. Global Type I Hyperlipoproteinemia Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Type I Hyperlipoproteinemia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Pradigastat Sodium Table 17. Major Manufacturers of Lomitapide Mesylate Table 18. Major Manufacturers of Alipogene Tiparvovec Table 19. Major Manufacturers of ISIS-APOCIIIRx Table 20. Major Manufacturers of CAT-2003 Table 21. Major Manufacturers of Others Table 22. Global Type I Hyperlipoproteinemia Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (W Units) Table 24. Global Type I Hyperlipoproteinemia Drug Sales by Type (2027-2032) & (W Units) Table 25. Global Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2021-2026) Table 26. Global Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2027-2032) Table 27. Global Type I Hyperlipoproteinemia Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 28. Global Type I Hyperlipoproteinemia Drug Revenue by Type (2021-2026) & (W Units) Table 29. Global Type I Hyperlipoproteinemia Drug Revenue by Type (2027-2032) & (W Units) Table 30. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Type (2021-2026) Table 31. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Others Table 35. Global Type I Hyperlipoproteinemia Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (W Units) Table 37. Global Type I Hyperlipoproteinemia Drug Sales by Application (2027-2032) & (W Units) Table 38. Global Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2021-2026) Table 39. Global Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2027-2032) Table 40. Global Type I Hyperlipoproteinemia Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 41. Global Type I Hyperlipoproteinemia Drug Revenue by Application (2021-2026) & (W Units) Table 42. Global Type I Hyperlipoproteinemia Drug Revenue by Application (2027-2032) & (W Units) Table 43. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Application (2021-2026) Table 44. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Application (2027-2032) Table 45. Global Type I Hyperlipoproteinemia Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Type I Hyperlipoproteinemia Drug Sales by Region (2021-2026) & (W Units) Table 47. Global Type I Hyperlipoproteinemia Drug Sales Market Share by Region (2021-2026) Table 48. Global Type I Hyperlipoproteinemia Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 49. Global Type I Hyperlipoproteinemia Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Type I Hyperlipoproteinemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 51. North America Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026) & (W Units) Table 52. North America Type I Hyperlipoproteinemia Drug Sales by Country (2027-2032) & (W Units) Table 53. Europe Type I Hyperlipoproteinemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Europe Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026) & (W Units) Table 55. Europe Type I Hyperlipoproteinemia Drug Sales by Country (2027-2032) & (W Units) Table 56. Asia Pacific Type I Hyperlipoproteinemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Asia Pacific Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026) & (W Units) Table 58. Asia Pacific Type I Hyperlipoproteinemia Drug Sales by Country (2027-2032) & (W Units) Table 59. South America, Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. South America, Middle East and Africa Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026) & (W Units) Table 61. South America, Middle East and Africa Type I Hyperlipoproteinemia Drug Sales by Country (2027-2032) & (W Units) Table 62. Global Type I Hyperlipoproteinemia Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Type I Hyperlipoproteinemia Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Type I Hyperlipoproteinemia Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Region (2021-2026) Table 66. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Region (2027-2032) Table 67. Aegerion Pharmaceuticals, Inc. Company Information Table 68. Aegerion Pharmaceuticals, Inc. Business Overview Table 69. Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio Table 71. Aegerion Pharmaceuticals, Inc. Recent Development Table 72. Catabasis Pharmaceuticals, Inc. Company Information Table 73. Catabasis Pharmaceuticals, Inc. Business Overview Table 74. Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio Table 76. Catabasis Pharmaceuticals, Inc. Recent Development Table 77. Isis Pharmaceuticals, Inc. Company Information Table 78. Isis Pharmaceuticals, Inc. Business Overview Table 79. Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio Table 81. Isis Pharmaceuticals, Inc. Recent Development Table 82. uniQure N.V. Company Information Table 83. uniQure N.V. Business Overview Table 84. uniQure N.V. Type I Hyperlipoproteinemia Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. uniQure N.V. Type I Hyperlipoproteinemia Drug Product Portfolio Table 86. uniQure N.V. Recent Development Table 87. Novartis AG Company Information Table 88. Novartis AG Business Overview Table 89. Novartis AG Type I Hyperlipoproteinemia Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Novartis AG Type I Hyperlipoproteinemia Drug Product Portfolio Table 91. Novartis AG Recent Development Table 92. Key Raw Materials Table 93. Raw Materials Key Suppliers Table 94. Type I Hyperlipoproteinemia Drug Distributors List Table 95. Type I Hyperlipoproteinemia Drug Customers List Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Type I Hyperlipoproteinemia Drug Product Image Figure 2. Global Type I Hyperlipoproteinemia Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Type I Hyperlipoproteinemia Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Type I Hyperlipoproteinemia Drug Sales (2021-2032) & (W Units) Figure 5. Global Type I Hyperlipoproteinemia Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Type I Hyperlipoproteinemia Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Pradigastat Sodium Image Figure 9. Lomitapide Mesylate Image Figure 10. Alipogene Tiparvovec Image Figure 11. ISIS-APOCIIIRx Image Figure 12. CAT-2003 Image Figure 13. Others Image Figure 14. Global Type I Hyperlipoproteinemia Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Type I Hyperlipoproteinemia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2021-2032) Figure 17. Global Type I Hyperlipoproteinemia Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Type I Hyperlipoproteinemia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Type I Hyperlipoproteinemia Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Type I Hyperlipoproteinemia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2021-2032) Figure 26. Global Type I Hyperlipoproteinemia Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Type I Hyperlipoproteinemia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 30. North America Type I Hyperlipoproteinemia Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Canada Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Mexico Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Type I Hyperlipoproteinemia Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. France Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. U.K. Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Italy Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Netherlands Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Type I Hyperlipoproteinemia Drug Sales Market Share by Country (2021-2032) Figure 43. China Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Japan Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South Korea Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Southeast Asia Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. India Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Australia Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South Africa Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Saudi Arabia Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Turkey Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Argentina Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. UAE Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Egypt Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Chile Type I Hyperlipoproteinemia Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Global Type I Hyperlipoproteinemia Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Type I Hyperlipoproteinemia Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Type I Hyperlipoproteinemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Type I Hyperlipoproteinemia Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Type I Hyperlipoproteinemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Type I Hyperlipoproteinemia Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Type I Hyperlipoproteinemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Type I Hyperlipoproteinemia Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Type I Hyperlipoproteinemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Type I Hyperlipoproteinemia Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Type I Hyperlipoproteinemia Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Pradigastat Sodium
  • Lomitapide Mesylate
  • Alipogene Tiparvovec
  • ISIS-APOCIIIRx
  • CAT-2003
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Aegerion Pharmaceuticals, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • Isis Pharmaceuticals, Inc.
  • uniQure N.V.
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Type I Hyperlipoproteinemia Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Type I Hyperlipoproteinemia Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Type I Hyperlipoproteinemia Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Type I Hyperlipoproteinemia Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Type I Hyperlipoproteinemia Drug Market Dynamics
  1. 2.1 Type I Hyperlipoproteinemia Drug Industry Trends
  2. 2.2 Type I Hyperlipoproteinemia Drug Industry Drivers
  3. 2.3 Type I Hyperlipoproteinemia Drug Industry Opportunities and Challenges
  4. 2.4 Type I Hyperlipoproteinemia Drug Industry Restraints
3 Type I Hyperlipoproteinemia Drug Market by Manufacturers
  1. 3.1 Global Type I Hyperlipoproteinemia Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Type I Hyperlipoproteinemia Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Type I Hyperlipoproteinemia Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Type I Hyperlipoproteinemia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Type I Hyperlipoproteinemia Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Type I Hyperlipoproteinemia Drug Manufacturers, Product Type & Application
  7. 3.7 Global Type I Hyperlipoproteinemia Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Type I Hyperlipoproteinemia Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Type I Hyperlipoproteinemia Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Type I Hyperlipoproteinemia Drug Tier 1, Tier 2, and Tier 3
4 Type I Hyperlipoproteinemia Drug Market by Type
  1. 4.1 Type I Hyperlipoproteinemia Drug Type Introduction
  2. 4.1.1 Pradigastat Sodium
  3. 4.1.2 Lomitapide Mesylate
  4. 4.1.3 Alipogene Tiparvovec
  5. 4.1.4 ISIS-APOCIIIRx
  6. 4.1.5 CAT-2003
  7. 4.1.6 Others
  8. 4.2 Global Type I Hyperlipoproteinemia Drug Sales by Type
  9. 4.2.1 Global Type I Hyperlipoproteinemia Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Type I Hyperlipoproteinemia Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Type I Hyperlipoproteinemia Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Type I Hyperlipoproteinemia Drug Revenue by Type
  13. 4.3.1 Global Type I Hyperlipoproteinemia Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Type I Hyperlipoproteinemia Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Type (2021-2032)
5 Type I Hyperlipoproteinemia Drug Market by Application
  1. 5.1 Type I Hyperlipoproteinemia Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Type I Hyperlipoproteinemia Drug Sales by Application
  6. 5.2.1 Global Type I Hyperlipoproteinemia Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Type I Hyperlipoproteinemia Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Type I Hyperlipoproteinemia Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Type I Hyperlipoproteinemia Drug Revenue by Application
  10. 5.3.1 Global Type I Hyperlipoproteinemia Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Type I Hyperlipoproteinemia Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Application (2021-2032)
6 Global Type I Hyperlipoproteinemia Drug Sales by Region
  1. 6.1 Global Type I Hyperlipoproteinemia Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Type I Hyperlipoproteinemia Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Type I Hyperlipoproteinemia Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Type I Hyperlipoproteinemia Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Type I Hyperlipoproteinemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Type I Hyperlipoproteinemia Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Type I Hyperlipoproteinemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Type I Hyperlipoproteinemia Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Type I Hyperlipoproteinemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Type I Hyperlipoproteinemia Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Type I Hyperlipoproteinemia Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Type I Hyperlipoproteinemia Drug Revenue by Region
  1. 7.1 Global Type I Hyperlipoproteinemia Drug Revenue by Region
  2. 7.1.1 Global Type I Hyperlipoproteinemia Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Type I Hyperlipoproteinemia Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Type I Hyperlipoproteinemia Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Type I Hyperlipoproteinemia Drug Revenue (2021-2032)
  8. 7.2.2 North America Type I Hyperlipoproteinemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Type I Hyperlipoproteinemia Drug Revenue (2021-2032)
  11. 7.3.2 Europe Type I Hyperlipoproteinemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Type I Hyperlipoproteinemia Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Type I Hyperlipoproteinemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Type I Hyperlipoproteinemia Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Type I Hyperlipoproteinemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Aegerion Pharmaceuticals, Inc.
  2. 8.1.1 Aegerion Pharmaceuticals, Inc. Company Information
  3. 8.1.2 Aegerion Pharmaceuticals, Inc. Business Overview
  4. 8.1.3 Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio
  6. 8.1.5 Aegerion Pharmaceuticals, Inc. Recent Developments
  7. 8.2 Catabasis Pharmaceuticals, Inc.
  8. 8.2.1 Catabasis Pharmaceuticals, Inc. Company Information
  9. 8.2.2 Catabasis Pharmaceuticals, Inc. Business Overview
  10. 8.2.3 Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio
  12. 8.2.5 Catabasis Pharmaceuticals, Inc. Recent Developments
  13. 8.3 Isis Pharmaceuticals, Inc.
  14. 8.3.1 Isis Pharmaceuticals, Inc. Company Information
  15. 8.3.2 Isis Pharmaceuticals, Inc. Business Overview
  16. 8.3.3 Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio
  18. 8.3.5 Isis Pharmaceuticals, Inc. Recent Developments
  19. 8.4 uniQure N.V.
  20. 8.4.1 uniQure N.V. Company Information
  21. 8.4.2 uniQure N.V. Business Overview
  22. 8.4.3 uniQure N.V. Type I Hyperlipoproteinemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 uniQure N.V. Type I Hyperlipoproteinemia Drug Product Portfolio
  24. 8.4.5 uniQure N.V. Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Type I Hyperlipoproteinemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Type I Hyperlipoproteinemia Drug Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Type I Hyperlipoproteinemia Drug Value Chain Analysis
  2. 9.1.1 Type I Hyperlipoproteinemia Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Type I Hyperlipoproteinemia Drug Production Mode & Process
  6. 9.2 Type I Hyperlipoproteinemia Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Type I Hyperlipoproteinemia Drug Distributors
  9. 9.2.3 Type I Hyperlipoproteinemia Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst